Abstract
A multifunctional nanobody-drug conjugate (NDC) was constructed in this work for the targeted delivery of a platinum prodrug and an MRI contrast agent. The NDC can be specifically internalized into EGFR positive cancer cells, resulting in higher therapeutic effect and lower side-effects relative to cisplatin. The Gd-binding domain enables the in situ detection of the drug distribution in vivo.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects
-
Cattle
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Chelating Agents / chemistry
-
Cisplatin / therapeutic use
-
Contrast Media / chemistry
-
Contrast Media / therapeutic use*
-
ErbB Receptors / immunology
-
Gadolinium / chemistry
-
Humans
-
Magnetic Resonance Imaging / methods
-
Mice, Inbred BALB C
-
Organoplatinum Compounds / chemistry
-
Organoplatinum Compounds / therapeutic use*
-
Prodrugs / chemistry
-
Prodrugs / therapeutic use*
-
Recombinant Fusion Proteins / chemistry
-
Recombinant Fusion Proteins / immunology*
-
Single-Domain Antibodies / immunology*
Substances
-
Antineoplastic Agents
-
Chelating Agents
-
Contrast Media
-
Organoplatinum Compounds
-
Prodrugs
-
Recombinant Fusion Proteins
-
Single-Domain Antibodies
-
Gadolinium
-
ErbB Receptors
-
Cisplatin